



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

February 19, 2020

Alison Lawton  
Chief Executive Officer  
Kaleido Biosciences, Inc.  
65 Hayden Avenue  
Lexington, MA 02421

**Re: Kaleido Biosciences, Inc.  
Form 8-K  
Exhibit No. 10.1 Credit Agreement, dated December 31, 2019, by and among Kaleido  
Biosciences, Inc., Cadena Bio, Inc. and Hercules Capital, Inc.  
Filed January 3, 2020  
File No. 001-38822**

Dear Ms. Lawton:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance